# A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma

> **NCT04362007** · PHASE1,PHASE2 · TERMINATED · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 8 (actual)

## Conditions studied

- Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)

## Interventions

- **DRUG:** ASTX660
- **DRUG:** ASTX660
- **DRUG:** ASTX660

## Key facts

- **NCT ID:** NCT04362007
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-14
- **Primary completion:** 2024-11-30
- **Final completion:** 2024-11-30
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** The study was terminated early due to Sponsor decision, the decision to terminate was not based on any safety concerns.
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04362007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04362007, "A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04362007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*